European Companies Search Engine
EU funding (€3,896,148): Deciphering PI3K biology in health and disease Hor11 Aug 2015 EU Research and Innovation programme "Horizon"
Text
Deciphering PI3K biology in health and disease
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of human cancers. Therefore, PI3Ks have emerged as important targets for drug discovery and, during 2014, the first PI3K inhibitor was approved by FDA in the US for the treatment of a lymphocytic leukaemia. Nonetheless, our understanding of PI3K-mediated signalling is still poor and only a fraction of the potential therapeutic applications have been addressed so far, leaving a large amount of translational work unexplored. Europe features a set of top quality research institutions and pharmaceutical companies focused on PI3K studies but their activities have been so far scattered. This proposal fills this gap by providing a multidisciplinary network (biochemistry, mouse studies, disease models, drug development, software development) and an unprecedented training opportunity from the bench to the bedside (from pre-clinical discoveries to clinical trials), through cutting edge molecular biology, drug discovery and clinical trial organization. The proposal is aimed at training young investigators in deep understanding of the different PI3K isoforms in distinct tissues and to translate this knowledge into a new generation of PI3K inhibitors, treatment modalities and into identify new uses for existing PI3K inhibitors.
Funded Companies:
| Company name | Funding amount |
| ? | |
| ARIVIS AG | €214,603 |
| Centre Europeen de Recherche en Biologie et Medecine | €262,876 |
| FORSCHUNGSVERBUND BERLIN e. V. | €498,433 |
| Fundacio Institut D'Investigacio Biomedica de Bellvitge | €530,173 |
| €247,873 | |
| Institut National de la Sante et de la Recherche Medicale | €525,751 |
| €440,297 | |
| The Chancellor Masters and Scholars of the University of Cambridge | €106,279 |
| €265,227 | |
| Universita Degli Studi DI Torino | €258,061 |
| €546,576 |
Source: https://cordis.europa.eu/project/id/675392
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Institut Clinique de la Souris, Illkirch-Graffenstaden, France.
The visualizations for "Institut Clinique de la Souris - EU funding (€3,896,148): Deciphering PI3K biology in health and disease"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
